Loading clinical trials...
Loading clinical trials...
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Conditions
Interventions
Nitazoxanide (NTZ)
Pegylated interferon alfa-2a (PEG)
+1 more
Locations
18
United States
Alabama Therapeutics CRS
Birmingham, Alabama, United States
UCLA CARE Center CRS
Los Angeles, California, United States
Stanford AIDS Clinical Trials Unit CRS
Palo Alto, California, United States
UCSD Antiviral Research Center CRS
San Diego, California, United States
Ucsf Hiv/Aids Crs
San Francisco, California, United States
Massachusetts General Hospital CRS (MGH CRS)
Boston, Massachusetts, United States
Start Date
January 1, 2010
Primary Completion Date
November 1, 2010
Completion Date
January 1, 2012
Last Updated
November 4, 2021
NCT06857071
NCT06694805
NCT04142047
NCT07428330
NCT05398185
NCT07225530
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions